SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ZIM Integrated Shipping Services Ltd. engages in the provision of shipping and logistics services. It offers shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. The company was founded on June 7, 1945 and is headquartered in Haifa, Israel.

Zim Integrated Shipping Services Ltd

ZIM Integrated Shipping Services is trending as Hapag-Lloyd confirmed a signed agreement to acquire the company for $35 per share, representing a significant premium, following ZIM's board rejecting a lower management-led bid and entertaining multiple strategic offers. The community is actively debating the deal's finality, potential for a short squeeze, and the possibility of continued dividends or even a higher offer given geopolitical complexities and ZIM's perceived undervaluation.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending with the community highly anticipating imminent topline Phase 3 superiority data for its wet AMD treatment, Axpaxli, which many believe will trigger a significant stock surge and intensified speculation of a sweetened acquisition offer from Sanofi.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Infleqtion Inc. - Ordinary Shares - Class A

Churchill Capital Corp X 

Infleqtion (formerly CCCX) is garnering immense investor excitement ahead of its NYSE debut under the ticker INFQ, driven by a highly successful merger with minimal redemptions, a landmark NASA contract, and community sentiment touting its undervalued position as a leader in quantum technology.

Masimo Corp. is a global technology company, which engages in the development, manufacture, and marketing of patient monitoring technologies, and automation and connectivity solutions. Its products include remote patient monitoring, connectivity, and hospital automation solutions, including Masimo Patient SafetyNet, Masimo Patient SafetyNet Surveillance, Masimo SafetyNet, Masimo SafetyNet-Open, Replica, Iris, MyView, UniView, Uniview: 60, Trace, Masimo Sleep, Centroid, and Bridge. It operates through the following segments: Healthcare and Non-Healthcare. The Healthcare segment develops, manufactures, and markets a variety of noninvasive monitoring technologies and hospital automation solutions and therapeutics. The Non-Healthcare segment designs, develops, manufactures, markets and sells a broad portfolio of premium, high-performance audio products and services. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.

Masimo Corp

A significant patent infringement win against Apple regarding blood-oxygen monitoring technology in Apple Watches and a reinstated import ban are driving Masimo's conversation. This positive legal development contrasts with recent substantially lowered preliminary revenue guidance and an activist investor's ongoing push for strategic changes and board representation, creating divided community sentiment.

Corsair Gaming, Inc. designs and supplies hardware components for personal computers. It operates through the Gamer and Creator Peripherals, and Gaming Components and Systems segments. The Gamer and Creator Peripherals segment offers gaming keyboards, mice, headsets, controllers, and gaming gear including capture cards, Stream Decks, USB microphones, studio accessories, and EpocCam software, as well as coaching and training services. The Gaming Components and Systems segment focuses on creating power supply units, or PSUs, cooling solutions, computer cases, DRAM modules, prebuilt, and custom-built gaming PCs. The company was founded by Andrew J. Paul in 1994 and is headquartered in Milpitas, CA.

Corsair Gaming Inc

Corsair Gaming is trending following robust earnings, a newly approved $50 million share repurchase program, and a notable spike in short borrowing rates. The community is actively discussing a potential short squeeze, highlighting the company's strong performance and its advantageous position in the memory market due to rising RAM prices and reduced competition.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk is drawing significant attention as its stock sits at multi-year lows, driven by widespread investor frustration over a recent CFO change, perceived management silence, and broader ad-tech sector pressures. Community sentiment is sharply polarized between those warning of further declines due to valuation concerns and others seeing a generational buying opportunity ahead of its upcoming earnings report.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is drawing intense investor attention ahead of upcoming Phase 3 clinical data for its COMP360 psilocybin therapy in treatment-resistant depression, with the community widely anticipating the critical MADRS score to determine the stock's immediate future. This pivotal readout is seen as a major catalyst for the company and the nascent psychedelic therapeutics sector, positioning CMPS as a potential first-mover in a field many believe is on the cusp of significant regulatory and commercial breakthroughs.

SSR Mining, Inc. is a gold company with assets located in four jurisdictions: the USA, Turkiye, Canada, and Argentina, which engages in the operation, acquisition, exploration and development of precious metal resource properties. The firm produces gold ore as well as copper, silver, lead and zinc concentrates. It operates through the following business segments: Copler, Marigold, Seabee and Puna. The Copler, Marigold, Seabee, and Puna segments represent its four operating mine sites. The company was founded on December 11, 1946 and is headquartered in Denver, CO.

SSR Mining Inc

SSR Mining is gaining traction ahead of its highly anticipated earnings, with the community discussing expectations for a significant EPS increase driven by robust gold prices and strategic mine contributions, despite lingering concerns over the Copler mine incident.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is trending as recent softer inflation data, flat retail sales, and rising jobless claims intensify community expectations for earlier Fed rate cuts, driving a rally amid a 'flight to safety' narrative. However, fierce debate persists over the reliability of economic data and the long-term trajectory for bond yields.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

Bitcoin is trending as recent ETF outflows and a significant price correction ignite intense community debate; while many voice short-term bearish concerns, others view the downturn as a strategic accumulation phase before a potential rebound.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company’s FDA-cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S.&nbsp;</li><li>With this step, ART100 moves from regulatory clearance to active commercial availability, the company said.</li><li>Earlier, Inspira announced a non-binding term sheet for a proposed two-part deal to acquire an advanced liquid biopsy diagnostics business</li></ul>Shares of Inspira Technologies OXY (IINN) popped over 28% in pre-market trading on Monday after Israel’s largest health services provider approved the procurement of its FDA-cleared ART100 platform.<a href="https://stocktwits.com/symbol/IINN">IINN shares</a> gave up premarket gains and fell around 3% after the opening bell.&nbsp;The company secured approval from Clalit Health Services’ Medical Equipment Committee, allowing its INSPIRA ART100 system to be immediately procured and deployed across a healthcare network serving roughly 4.9 million members.<h2 class="st-heading-2">ART100 Regulatory Clearance</h2>With this step, ART100 moves from regulatory clearance to active commercial availability, marking a significant growth opportunity for Inspira and strong clinical validation.“By securing this approval, we are laying the foundation for potentially long-term, high-quality revenue. This validation from a world-class, data-driven health ecosystem serves as a powerful reference case as we accelerate our commercialization efforts in the U.S. and other global markets,” said Dagi Ben-Noon, CEO of Inspira Technologies.The company’s FDA-cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S. and for (Extracorporeal Membrane Oxygenation) ECMO procedures outside the U.S.<h2 class="st-heading-2">Top U.S. Medical Center Clears ART100&nbsp;</h2>In January, Inspira Technologies’ ART100 system completed clinical evaluation at a top U.S. academic medical centre and moved into the budgeted procurement stage. The system successfully treated about 30 patients across surgeries, transplants, and other critical procedures, leading to its adoption into routine clinical workflows.&nbsp;With the evaluation phase now closed, the hospital has begun an internal process to purchase multiple ART100 units, pending final budget approval.Earlier, Inspira announced a non-binding term sheet for a proposed two-part deal to acquire an advanced liquid biopsy diagnostics business. The transaction also includes a planned $15 million strategic equity investment.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘extremely high’ message volumes.The stock has shed around 25% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

Why Did IINN Stock Surge 28% In Pre-Market Today?

The company won approval from Clalit Health Services to deploy its INSPIRA ART100 system across a network of around 4.9 million members.

Equity

All You Need to Know About Inspira Technologies OXY (IINN) Rating Upgrade to Buy

Inspira Technologies OXY (IINN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Inspira Technologies OXY B.H.N. (IINN) on Friday announced that it has received U.S. Patent approval for the core technology of its ART500 device.The firm stated that the device is key to penetrating the $20 billion estimated market for advanced respiratory support. The newly received patent provides protection at least until the year 2043, covering key claims related to the ART500’s functionality, design, and clinical applications.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IINN">IINN stock</a> stayed within ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:577/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_22_at_2_07_05_PM_png_792c0ec45d.webp" alt="IINN's Sentiment Meter and Message Volume as of 2:07 p.m. ET on Aug. 22, 2025 | Source: Stocktwits" width="577" height="61"><figcaption>IINN's Sentiment Meter and Message Volume as of 2:07 p.m. ET on Aug. 22, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user said that they are loading up on the shares of the company.<stembedurl>https://stocktwits.com/VSWeWork/message/626246424</stembedurl>Another, however, sounded disappointed at the stock’s performance.<stembedurl>https://stocktwits.com/Kyavic77/message/626229410</stembedurl>The ART500 system is designed to provide extracorporeal oxygenation at low flow rates while maintaining patient safety and treatment efficiency. According to the firm, this targets a patient population that requires respiratory support but may not be sick enough for traditional, high-flow ECMO systems.Inspira CEO Dagi Ben-Noon <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/08/22/3137823/0/en/Inspira-Receives-U-S-Patent-Approval-for-the-ART500-Core-Technology-Key-Patent-Positions-the-Company-to-Dominate-20-Billion-Estimated-Market.html">said</a> that the patent has profound business implications for the company. “While our ART100 system is already generating commercial momentum, this move fortifies our future and gives us the clear runway…,” he said.Earlier this month, Inspira <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/08/19/3135699/0/en/Inspira-Secures-27-Million-Government-Binding-Purchase-Order-for-ART100-Systems-with-Full-Payment-in-2025.html">said</a> that a national ministry of health in Africa has placed a $27 million binding purchase order for its ART100 systems. The purchase order provides for full contractual payment scheduled for completion during 2025.IINN stock is up by 17% this year and by about 9% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/gary-black-believes-these-are-five-things-that-could-initiate-tesla-rally/chsZeukRdKP">Gary Black Believes These Are The Five Things That Could Initiate A Tesla Rally</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Global stock market chart and trading board - stock photo

Inspira Technologies Receives US Patent Clearance For Core Technology Of Its ART500 Device: Retail Loads Up On The Stock 

The newly received patent provides protection at least until the year 2043, covering key claims related to the ART500 device’s functionality, design, and clinical applications.

Inspira Technologies Oxy B.H.N. Ltd. is a specialty medical device company, which engages in research, development, manufacturing, and marketing of proprietary life support technology with a vision to supersede traditional mechanical ventilators, or Mechanical Ventilation, which is the standard of care today for the treatment of acute respiratory failure. The company was founded by Dagi Shahar Ben Noon, Joe Hayon, and Udi Nussinovitch in July 2017 and is headquartered in Raanana, Israel.

Inspira Technologies Oxy B.H.N. Ltd

3%+ above current levels

Up 0–3%

Flat to down 3%

Down 3%+

The Nasdaq 100 continues to hinge on mega-cap tech and AI strength. With rate expectations shifting and valuations stretched, even a 3% move could signal a bigger trend. Is momentum building, or fading?

IINN
Inspira Technologies Oxy B.H.N. Ltd

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest IINN News

IINNInspira Technologies Oxy B.H.N. Ltd